News zum Sektor Gesundheit aus Asien

 

At close, HSI dropped 153 pts or 0.6% to 23,916. HSTI dropped 17 pts or 0.3% to 5,216. HSCEI fell 39 pts or 0.5% to 8,609. Market turnover reached $267.81 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $120.8, down 1.6%BABA (09988.HK) closed at $105.1, down 1%XIAOMI (01810.HK) closed at $57.5, down 1%TENCENT (00700.HK)......

Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers. (click here)....

At midday close, HSI dropped 148 pts or 0.6% to 23,921. HSTI dropped 24 pts or 0.5% to 5,209. HSCEI fell 36 pts or 0.4% to 8,611.Active Heavyweights:XIAOMI (01810.HK) closed at $57.4, down 1.2%MEITUAN (03690.HK) closed at $121.7, down 0.9%PING AN (02318.HK) closed at $49.7, down 0.8%HKEX (00388.HK) closed at $414.8, down 0.6%BAB......

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING,......

HBM, STNE, CNC, and CVS stand out for low P/CF ratios and strong value scores as investors seek quality in a cautious market....

There was HKD987.4 million and HKD22.7 million Southbound Trading net inflow to MEITUAN-W (03690.HK) and XIAOMI-W (01810.HK).There was HKD3.2 billion, HKD885.3 million and HKD739.9 million Southbound Trading net outflow from BABA-W (09988.HK), TENCENT (00700.HK) and AKESO (09926.HK).For Southbound Trading of Shanghai-Hong Kong S......

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT)....

At close, HSI dropped 151 pts or 0.6% to 24,069. HSTI dropped 35 pts or 0.7% to 5,233. HSCEI fell 76 pts or 0.9% to 8,648. Market turnover reached $231.25 billion.Active Heavyweights:XIAOMI (01810.HK) closed at $58.1, down 3.4%BABA (09988.HK) closed at $106.2, down 2.9%MEITUAN (03690.HK) closed at $122.8, down 2.5%HKEX (00388.HK......

HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's......

NextCell Pharma AB's ("NextCell" or "the Company") has entered into a strategic collaboration with FUJIFILM Biosciences Inc. to bring together their core competences in mesenchymal stromal cells (MSCs) and raw materials for the life science sector. The aim of the collaboration is to provide researchers and developers in the cell therapy field with an integrated offering – standardised MSC products, optimised culture media, and cryopreservation solutions. As part of the rebranding of Fujifilm Irvine Scientific to FUJIFILM Biosciences, we are re-publishing the press release originally issued...

At midday close, HSI dropped 232 pts or 1.0% to 23,989. HSTI dropped 63 pts or 1.2% to 5,205. HSCEI fell 108 pts or 1.2% to 8,616.Active Heavyweights:XIAOMI (01810.HK) closed at $57.5, down 4.4%BABA (09988.HK) closed at $105.5, down 3.6%MEITUAN (03690.HK) closed at $122.9, down 2.5%HKEX (00388.HK) closed at $417.6, down 1.3%TENC......

BEIJING, SHANGHAI and BOSTON, July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in......

- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of small molecule oral GLP-1 receptor agonist ASC30. - ASC30 oral once-daily tablet demonstrated up to 6.5% placebo-adjusted mean body weight......

Hudbay, StoneCo, Centene, and CVS stand out as top value picks for H2 2025 with strong cash flow and growth prospects....

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

Morgan Stanley released a research report, covering HENGRUI PHARMA (01276.HK), which possesses the most extensive and balanced product portfolio and pipeline among domestic pharmaceutical companies in China. The company estimated to have 47 new drugs approved for market launch between 2025 and 2027. Since 2018, the company has e......

Pharma - Die Schweizer Biotechfirma BioVersys hat eine Forschungs- und Lizenzvereinbarung mit dem japanischen Pharmaunternehmen Shionogi abgeschlossen....

BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE...

INNOVENT BIO (01801.HK)'s IBI363 (PD-1/IL-2alpha-bias bispecific antibody fusion protein product) has been highlighted by opinion leaders for its promising data and potential to become a key product in next-generation immuno-oncology (IO) treatment, Citi published a research report noting.In Citi's opinion, INNOVENT BIO ......

China's National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) jointly issued the 'Several Measures to Support the High-Quality Development of Innovative Drugs' on 1 July, marking the first time the two government departments have jointly introduced policies to support differentia......